Engaging community pharmacists to eliminate inadvertent doping in sports: A study of their knowledge on doping.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2021
accepted:
10
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
15
6
2022
Statut:
epublish
Résumé
This study aimed to evaluate the community pharmacists' knowledge of tackling the issue of inadvertent doping in Malaysia. A cross-sectional survey was conducted among 384 community pharmacists working in Malaysia using a self-administered questionnaire. All the respondents were pharmacists fully registered with the Pharmacy Board of Malaysia and had been working in the community setting for at least one year. Of the 426 community pharmacists approached, 384 community pharmacists participated in this study, giving a response rate of 90.14%. The majority of the respondents were females (63.5%), graduated from local universities (74.9%), with median years of practising as a community pharmacist of six years (interquartile range, IQR = 9 years). The respondents were found to have moderate levels of doping-related knowledge (median score of 52 out of 100). Anabolic steroids (95.8%), stimulants (78.6%) and growth factors (65.6%) were recognised as prohibited substances by most of the respondents. Around 65.9% did not recognise that inadvertent doping is also considered a doping violation. Most of them (90%) also have poor levels of knowledge of doping scenarios in the country. Community pharmacists in Malaysia have limited knowledge in the field of doping. More programmes and activities related to doping and drugs in sports should be held to enhance the community pharmacists' knowledge on the issue of inadvertent doping.
Identifiants
pubmed: 35687540
doi: 10.1371/journal.pone.0268878
pii: PONE-D-21-01079
pmc: PMC9187095
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268878Déclaration de conflit d'intérêts
There is no conflict of interest for all the authors.
Références
BMC Res Notes. 2017 Aug 11;10(1):396
pubmed: 28800770
J Am Pharm Assoc (2003). 2004 Jul-Aug;44(4):501-14; quiz 514-6
pubmed: 15372871
Integr Pharm Res Pract. 2021 May 31;10:43-50
pubmed: 34104633
Pharmacy (Basel). 2020 Jan 15;8(1):
pubmed: 31952349
Am J Pharm Educ. 2015 Oct 25;79(8):119
pubmed: 26689844
Clin Chem. 2011 Jul;57(7):969-76
pubmed: 21596947
J Am Pharm Assoc (2003). 2018 Jul - Aug;58(4S):S30-S36.e2
pubmed: 30006185
Am J Pharm Educ. 2020 May;84(5):7682
pubmed: 32577034
Int J Sport Nutr Exerc Metab. 2001 Sep;11(3):365-83
pubmed: 11591885
Food Chem Toxicol. 2018 May;115:447-450
pubmed: 29621580
J Sports Med Phys Fitness. 2016 Jun;56(6):817-24
pubmed: 25784399
Wien Klin Wochenschr. 2012 Jan;124(1-2):32-8
pubmed: 22038377
Br J Sports Med. 2003 Aug;37(4):356-7
pubmed: 12893725
Sports Med. 2010 Nov 1;40(11):961-80
pubmed: 20942511
Int J Drug Policy. 2013 Nov;24(6):579-88
pubmed: 23582632
Med Sport Sci. 2017;62:55-67
pubmed: 28571022